{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:09:54Z","timestamp":1779203394395,"version":"3.51.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005774","name":"Universitat de Barcelona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40273-026-01611-6","type":"journal-article","created":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T10:57:52Z","timestamp":1774177072000},"page":"705-725","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chronic Kidney Disease (CKD): Systematic Review of the Cost Effectiveness of SGLT2 Inhibitors and Other Novel Nephroprotective Drugs"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-0999","authenticated-orcid":false,"given":"Josep","family":"Darb\u00e0","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meritxell","family":"Ascanio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,22]]},"reference":[{"issue":"1","key":"1611_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12(1):7\u201311. https:\/\/doi.org\/10.1016\/j.kisu.2021.11.003.","journal-title":"Kidney Int Suppl"},{"key":"1611_CR2","unstructured":"World Health Organization. The top 10 causes of death. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death. Accessed 13 Mar 2026."},{"issue":"10440","key":"1611_CR3","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/s0140-6736(24)00685-8","volume":"403","author":"GBD 2021 Forecasting Collaborators","year":"2024","unstructured":"GBD 2021 Forecasting Collaborators. Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2204\u201356. https:\/\/doi.org\/10.1016\/s0140-6736(24)00685-8.","journal-title":"Lancet"},{"issue":"11","key":"1611_CR4","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1093\/ckj\/sfad101","volume":"16","author":"R Lo","year":"2023","unstructured":"Lo R, Narasaki Y, Lei S, Rhee CM. Management of traditional risk factors for the development and progression of chronic kidney disease. Clin Kidney J. 2023;16(11):1737\u201350. https:\/\/doi.org\/10.1093\/ckj\/sfad101.","journal-title":"Clin Kidney J"},{"issue":"3","key":"1611_CR5","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1016\/s2214-109x(23)00570-3","volume":"12","author":"AK Bello","year":"2024","unstructured":"Bello AK, Okpechi IG, Levin A, Ye F, Damster S, Arruebo S, et al. An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Glob Health. 2024;12(3):e382\u201395. https:\/\/doi.org\/10.1016\/s2214-109x(23)00570-3.","journal-title":"Lancet Glob Health"},{"key":"1611_CR6","doi-asserted-by":"crossref","unstructured":"KDIGO. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. https:\/\/kdigo.org\/wp-content\/uploads\/2024\/03\/KDIGO-2024-CKD-Guideline.pdf. Accessed 13 Mar 2026.","DOI":"10.22141\/2307-1257.13.2.2024.456"},{"issue":"8","key":"1611_CR7","doi-asserted-by":"publisher","first-page":"e1378","DOI":"10.1016\/s2214-109x(25)00198-6","volume":"13","author":"GBD 2023 Kidney Failure with Replacement Therapy Collaborators","year":"2025","unstructured":"GBD 2023 Kidney Failure with Replacement Therapy Collaborators. Global, regional, and national prevalence of kidney failure with replacement therapy and associated aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Glob Health. 2025;13(8):e1378\u201395. https:\/\/doi.org\/10.1016\/s2214-109x(25)00198-6.","journal-title":"Lancet Glob Health"},{"issue":"7","key":"1611_CR8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","volume":"20","author":"A Francis","year":"2024","unstructured":"Francis A, Harhay MN, Ong ACM, Tummalapalli SL, Ortiz A, Fogo AB, et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024;20(7):473\u201385. https:\/\/doi.org\/10.1038\/s41581-024-00820-6.","journal-title":"Nat Rev Nephrol"},{"issue":"24","key":"1611_CR9","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/nejmoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306. https:\/\/doi.org\/10.1056\/nejmoa1811744.","journal-title":"N Engl J Med"},{"issue":"15","key":"1611_CR10","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/nejmoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/nejmoa2024816.","journal-title":"N Engl J Med"},{"key":"1611_CR11","doi-asserted-by":"publisher","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327. https:\/\/doi.org\/10.1056\/nejmoa2204233.","DOI":"10.1056\/nejmoa2204233"},{"issue":"23","key":"1611_CR12","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/nejmoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329. https:\/\/doi.org\/10.1056\/nejmoa2025845.","journal-title":"N Engl J Med"},{"issue":"24","key":"1611_CR13","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/nejmoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252\u201363. https:\/\/doi.org\/10.1056\/nejmoa2110956.","journal-title":"N Engl J Med"},{"issue":"2","key":"1611_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/nejmoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/nejmoa2403347.","journal-title":"N Engl J Med"},{"key":"1611_CR15","unstructured":"US FDA. Approved drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm. Accessed 13 Mar 2026."},{"key":"1611_CR16","unstructured":"Exchange-rates.org. https:\/\/www.exchange-rates.org. Accessed 13 Mar 2026."},{"key":"1611_CR17","unstructured":"U.S. inflation calculator. https:\/\/www.usinflationcalculator.com\/. Accessed 13 Mar 2026."},{"issue":"1","key":"1611_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s13300-020-00968-x","volume":"12","author":"M Willis","year":"2021","unstructured":"Willis M, Nilsson A, Kellerborg K, Ball P, Roe R, Traina S, et al. Cost-effectiveness of canagliflozin added to standard of care for treating diabetic kidney disease (DKD) in patients with type 2 diabetes mellitus (T2DM) in England: estimates using the CREDEM-DKD model. Diabetes Ther. 2021;12(1):313\u201328. https:\/\/doi.org\/10.1007\/s13300-020-00968-x.","journal-title":"Diabetes Ther"},{"key":"1611_CR19","unstructured":"Single Technology Appraisal. Finerenone for treating chronic kidney disease in people with type 2 diabetes [ID3773]. Committee Papers. NICE. https:\/\/www.nice.org.uk\/guidance\/ta877\/evidence\/appraisal-consultation-committee-papers-pdf-11429938478. Accessed 13 Mar 2026."},{"issue":"12","key":"1611_CR20","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.2215\/cjn.03790322","volume":"17","author":"P McEwan","year":"2022","unstructured":"McEwan P, Darlington O, Miller R, McMurray JJV, Wheeler DC, Heerspink HJL, et al. Cost-effectiveness of dapagliflozin as a treatment for chronic kidney disease: a health-economic analysis of DAPA-CKD. Clin J Am Soc Nephrol. 2022;17(12):1730\u201341. https:\/\/doi.org\/10.2215\/cjn.03790322.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"1611_CR21","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1253\/circj.cj-22-0086","volume":"86","author":"S Kodera","year":"2022","unstructured":"Kodera S, Morita H, Nishi H, Takeda N, Ando J, Komuro I. Cost-effectiveness of dapagliflozin for chronic kidney disease in Japan. Circ J. 2022;86(12):2021\u20138. https:\/\/doi.org\/10.1253\/circj.cj-22-0086.","journal-title":"Circ J"},{"issue":"13","key":"1611_CR22","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1007\/s11606-021-07311-5","volume":"37","author":"RL Tisdale","year":"2022","unstructured":"Tisdale RL, Cusick MM, Aluri KZ, Handley TJ, Joyner AKC, Salomon JA, et al. Cost-effectiveness of dapagliflozin for non-diabetic chronic kidney disease. J Gen Intern Med. 2022;37(13):3380\u20137. https:\/\/doi.org\/10.1007\/s11606-021-07311-5.","journal-title":"J Gen Intern Med"},{"issue":"3","key":"1611_CR23","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s12325-021-02037-6","volume":"39","author":"K Vareesangthip","year":"2022","unstructured":"Vareesangthip K, Deerochanawong C, Thongsuk D, Pojchaijongdee N, Permsuwan U. Cost-utility analysis of dapagliflozin as an add-on to standard of care for patients with chronic kidney disease in Thailand. Adv Ther. 2022;39(3):1279\u201392. https:\/\/doi.org\/10.1007\/s12325-021-02037-6.","journal-title":"Adv Ther"},{"key":"1611_CR24","unstructured":"NCBI. CADTH reimbursement review. Finerenone (Kerendia). Therapeutic area: chronic kidney disease. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK594385\/. Accessed 13 Mar 2026."},{"issue":"1","key":"1611_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-02053-6","volume":"22","author":"SW Quist","year":"2023","unstructured":"Quist SW, van Schoonhoven AV, Bakker SJL, Pochopie\u0144 M, Postma MJ, van Loon JMT, et al. Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands. Cardiovasc Diabetol. 2023;22(1):328. https:\/\/doi.org\/10.1186\/s12933-023-02053-6.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1611_CR26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/13696998.2023.2174749","volume":"26","author":"A Swidan","year":"2023","unstructured":"Swidan A, Elsisi GH, Ibrahim MM, Aljazzar M, Tawfik Sallam H. Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait. J Med Econ. 2023;26(1):271\u201382. https:\/\/doi.org\/10.1080\/13696998.2023.2174749.","journal-title":"J Med Econ"},{"issue":"10","key":"1611_CR27","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1111\/dom.15201","volume":"25","author":"BN Nguyen","year":"2023","unstructured":"Nguyen BN, Mital S, Bugden S, Nguyen HV. Cost-effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes. Diabetes Obes Metab. 2023;25(10):3030\u20139. https:\/\/doi.org\/10.1111\/dom.15201.","journal-title":"Diabetes Obes Metab"},{"key":"1611_CR28","unstructured":"NICE. Single Technology Appraisal. Empagliflozin for treating chronic kidney disease [ID6131]. Committee papers. https:\/\/www.nice.org.uk\/guidance\/ta942\/evidence\/committee-papers-pdf-13252406077. Accessed 13 Mar 2026."},{"issue":"2","key":"1611_CR29","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s12325-024-03084-5","volume":"42","author":"A Igarashi","year":"2025","unstructured":"Igarashi A, Ohara K, Matsuda H, Morii J, Jagannathan S, Filomeno R. Cost-effectiveness analysis of finerenone for treatment of chronic kidney disease in patients with type 2 diabetes from Japanese payer perspective. Adv Ther. 2025;42(2):995\u20131008. https:\/\/doi.org\/10.1007\/s12325-024-03084-5.","journal-title":"Adv Ther"},{"issue":"12","key":"1611_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0315509","volume":"19","author":"B Slob","year":"2024","unstructured":"Slob B, Fens T, Weersma M, Postma M, Boersma C, de Jong L. Cost effectiveness of empagliflozin in adult patients with chronic kidney disease in the Netherlands. PLoS ONE. 2024;19(12):e0315509. https:\/\/doi.org\/10.1371\/journal.pone.0315509.","journal-title":"PLoS ONE"},{"issue":"11","key":"1611_CR31","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jamahealthforum.2024.3892","volume":"44","author":"H Groyer","year":"2024","unstructured":"Groyer H, Supiot R, Tardu J, Virely N, Sivignon M, San D, et al. Cost-effectiveness of empagliflozin (Jardiance\u00ae) in the treatment of patients with chronic kidney disease in France, based on the EMPA-KIDNEY Clinical Trial. Clin Drug Investig. 2024;44(11):811\u201328. https:\/\/doi.org\/10.1001\/jamahealthforum.2024.3892.","journal-title":"Clin Drug Investig"},{"issue":"10","key":"1611_CR32","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/14737167.2024.2382976","volume":"24","author":"P Lasalvia","year":"2024","unstructured":"Lasalvia P, V\u00e1squez M EC, Arango \u00c1lvarez JJ, Garcia-Padilla P. Cost-effectiveness of dapagliflozin plus standard treatment compared to standard therapy for the management of chronic kidney disease in Colombia. Expert Rev Pharmacoecon Outcomes Res. 2024;24(10):1133\u201343. https:\/\/doi.org\/10.1080\/14737167.2024.2382976.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"1611_CR33","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1080\/13696998.2024.2368990","volume":"27","author":"L Varghese","year":"2024","unstructured":"Varghese L, Chang PW, Juntarasiripas S, Pham H, Uster A. Cost-effectiveness of add-on empagliflozin versus standard of care in management of CKD in Malaysia, Thailand and Vietnam: Findings from a modelling study assessing an EMPA-KIDNEY eligible population, using CKD progression model. J Med Econ. 2024;27(1):836\u201348. https:\/\/doi.org\/10.1080\/13696998.2024.2368990.","journal-title":"J Med Econ"},{"issue":"1","key":"1611_CR34","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/13696998.2024.2357041","volume":"27","author":"M Ramos","year":"2024","unstructured":"Ramos M, Gerlier L, Uster A, Muttram L, Frankel AH, Lamotte M. Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom. J Med Econ. 2024;27(1):777\u201385. https:\/\/doi.org\/10.1080\/13696998.2024.2357041.","journal-title":"J Med Econ"},{"issue":"3","key":"1611_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0296067","volume":"19","author":"SK Lim","year":"2024","unstructured":"Lim SK, Lee SWH. Cost-effectiveness analysis of dapagliflozin for people with chronic kidney disease in Malaysia. PLoS ONE. 2024;19(3):e0296067. https:\/\/doi.org\/10.1371\/journal.pone.0296067.","journal-title":"PLoS ONE"},{"issue":"2","key":"1611_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae025","volume":"17","author":"P McEwan","year":"2024","unstructured":"McEwan P, Davis JA, Gabb PD, Wheeler DC, Rossing P, Chertow GM, et al. Dapagliflozin in chronic kidney disease: Cost-effectiveness beyond the DAPA-CKD trial. Clin Kidney J. 2024;17(2):sfae025. https:\/\/doi.org\/10.1093\/ckj\/sfae025.","journal-title":"Clin Kidney J"},{"issue":"8","key":"1611_CR37","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1007\/s12325-024-02906-w","volume":"41","author":"J Ming","year":"2024","unstructured":"Ming J, Hong G, Xu Y, Mernagh P, Pochopie\u0144 M, Li H. Cost-effectiveness of finerenone in addition to standard of care for patients with chronic kidney disease and type 2 diabetes in China. Adv Ther. 2024;41(8):3138\u201358. https:\/\/doi.org\/10.1007\/s12325-024-02906-w.","journal-title":"Adv Ther"},{"key":"1611_CR38","unstructured":"NICE. Single Technology Appraisal. Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]. Committee papers. https:\/\/www.nice.org.uk\/guidance\/ta1035\/evidence\/committee-papers-pdf-15239391805. Accessed 13 Mar 2026."},{"key":"1611_CR39","unstructured":"NICE. Single Technology Appraisal. Sparsentan for treating primary IgA nephropathy [ID6308]. Committee papers. https:\/\/www.nice.org.uk\/guidance\/ta1074\/evidence\/draft-guidance-consultation-committee-papers-pdf-15368536909. Accessed 13 Mar 2026."},{"issue":"85","key":"1611_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103338","volume":"8","author":"J Zhou","year":"2025","unstructured":"Zhou J, Williams C, Staplin N, Judge PK, Mayne KJ, Agrawal N, et al. Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial. EClinicalMedicine. 2025;8(85):103338. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103338.","journal-title":"EClinicalMedicine."},{"issue":"7","key":"1611_CR41","doi-asserted-by":"publisher","first-page":"641","DOI":"10.18553\/jmcp.2025.31.7.641","volume":"31","author":"J Kim","year":"2025","unstructured":"Kim J, Wang S, Marin M, Sikirica S, Anderson M, Shafrin J. Cost-effectiveness analysis model for sotagliflozin compared with insulin monotherapy for patients with type 1 diabetes and chronic kidney disease. J Manag Care Spec Pharm. 2025;31(7):641\u201350. https:\/\/doi.org\/10.18553\/jmcp.2025.31.7.641.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"1611_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjph-2024-001288","volume":"3","author":"SW Quist","year":"2025","unstructured":"Quist SW, van Loon J, Bakker S, Pochopi\u00e9n M, Postma MJ, Paulissen J. Cost-effectiveness of treatment with finerenone in mild to advanced stage chronic kidney disease patients with type 2 diabetes from a societal perspective. BMJ Public Health. 2025;3(1):e001288. https:\/\/doi.org\/10.1136\/bmjph-2024-001288.","journal-title":"BMJ Public Health"},{"issue":"6","key":"1611_CR43","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1007\/s12325-025-03157-z","volume":"42","author":"A Igarashi","year":"2025","unstructured":"Igarashi A, Tachimori H, Maruyama-Sakurai K, Segawa Y, Takagi H, Akiyama H, et al. Cost-effectiveness analysis of SGLT2 inhibitors for cardio-renal-metabolic disease based on data from Japanese studies. Adv Ther. 2025;42(6):2888\u2013905. https:\/\/doi.org\/10.1007\/s12325-025-03157-z.","journal-title":"Adv Ther"},{"issue":"1","key":"1611_CR44","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/13696998.2025.2474887","volume":"28","author":"P Dilokthornsakul","year":"2025","unstructured":"Dilokthornsakul P, Susantitaphong P, Satirapoj B, Singhan W, Ophascharoensuk V. Cost-utility analysis of empagliflozin on chronic kidney disease progression in Thailand. J Med Econ. 2025;28(1):387\u201397. https:\/\/doi.org\/10.1080\/13696998.2025.2474887.","journal-title":"J Med Econ"},{"issue":"1","key":"1611_CR45","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/13696998.2025.2451526","volume":"28","author":"D Cherney","year":"2025","unstructured":"Cherney D, Drzewiecka A, Folkerts K, Levy P, Millier A, Morris S, et al. Cost-effectiveness of finerenone therapy for patients with chronic kidney disease and type 2 diabetes in England & Wales: results of the FINE-CKD model. J Med Econ. 2025;28(1):196\u2013206. https:\/\/doi.org\/10.1080\/13696998.2025.2451526.","journal-title":"J Med Econ"},{"issue":"1","key":"1611_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-81747-7","volume":"15","author":"N Chitpim","year":"2025","unstructured":"Chitpim N, Leelahavarong P, Prawjaeng J, Ittiphisit S, Srinonprasert V, Kongmalai T. A cost-utility analysis of adding SGLT2 inhibitors for the management of type 2 diabetes with chronic kidney disease in Thailand. Sci Rep. 2025;15(1):249. https:\/\/doi.org\/10.1038\/s41598-024-81747-7.","journal-title":"Sci Rep"},{"issue":"10","key":"1611_CR47","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1007\/s00125-025-06498-0","volume":"68","author":"TA Kalhan","year":"2025","unstructured":"Kalhan TA, Luo M, Chai JH, Tai ES, Lim SC, Coffman TM, et al. Health economic evaluation of a risk-stratified intervention in diabetic kidney disease. Diabetologia. 2025;68(10):2227\u201339. https:\/\/doi.org\/10.1007\/s00125-025-06498-0.","journal-title":"Diabetologia"},{"issue":"1","key":"1611_CR48","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/dom.15997","volume":"27","author":"C Zheng","year":"2025","unstructured":"Zheng C, Wu J, Li N, Wei X, Huang Z, Chen L, et al. Cost-effectiveness of finerenone added to standard of care for patients with type 2 diabetes-related chronic kidney disease in the United States. Diabetes Obes Metab. 2025;27(1):165\u201373. https:\/\/doi.org\/10.1111\/dom.15997.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1611_CR49","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1053\/j.ajkd.2021.09.014","volume":"79","author":"OS Reifsnider","year":"2022","unstructured":"Reifsnider OS, Kansal AR, Wanner C, Pfarr E, Koitka-Weber A, Brand SB, et al. Cost-effectiveness of empagliflozin in patients with diabetic kidney disease in the United States: findings based on the EMPA-REG OUTCOME trial. Am J Kidney Dis. 2022;79(6):796\u2013806. https:\/\/doi.org\/10.1053\/j.ajkd.2021.09.014.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"1611_CR50","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1111\/dom.15832","volume":"26","author":"K Maruyama-Sakurai","year":"2024","unstructured":"Maruyama-Sakurai K, Tachimori H, Saito E, Kohsaka S, Segawa Y, Miyata H, et al. Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in the treatment of diabetic nephropathy in Japan. Diabetes Obes Metab. 2024;26(12):5546\u201355. https:\/\/doi.org\/10.1111\/dom.15832.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1611_CR51","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40261-022-01160-8","volume":"42","author":"TM Abegaz","year":"2022","unstructured":"Abegaz TM, Diaby V, Sherbeny F, Ali AA. Cost effectiveness of dapagliflozin added to standard of care for the management of diabetic nephropathy in the USA. Clin Drug Investig. 2022;42(6):501\u201311. https:\/\/doi.org\/10.1007\/s40261-022-01160-8.","journal-title":"Clin Drug Investig"},{"issue":"9","key":"1611_CR52","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s40261-025-01462-7","volume":"45","author":"T Qiu","year":"2025","unstructured":"Qiu T, Li P, Yan D. Cost-effectiveness of adding dapagliflozin and empagliflozin to standard treatment for diabetic kidney disease in China. Clin Drug Investig. 2025;45(9):651\u201364. https:\/\/doi.org\/10.1007\/s40261-025-01462-7.","journal-title":"Clin Drug Investig"},{"key":"1611_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112421","volume":"228","author":"HH Wang","year":"2025","unstructured":"Wang HH, Chiu YW, Chung CY, Liao YM, Lee YH, Kuo HM, et al. Clinical efficacy and cost effectiveness of SGLT2i in diabetic nephropathy: a large population-based study. Diabetes Res Clin Pract. 2025;228:112421. https:\/\/doi.org\/10.1016\/j.diabres.2025.112421.","journal-title":"Diabetes Res Clin Pract"},{"issue":"20 Suppl.","key":"1611_CR54","doi-asserted-by":"publisher","first-page":"S375","DOI":"10.37765\/ajmc.2021.88808","volume":"27","author":"MT Pochopie\u0144","year":"2021","unstructured":"Pochopie\u0144 MT, Cherney DZI, Folkerts K, Levy P, Millier A, Morris S, et al. FINE-CKD model to evaluate economic value of finerenone in patients with chronic kidney disease and type 2 diabetes. Am J Manag Care. 2021;27(20 Suppl.):S375\u201382. https:\/\/doi.org\/10.37765\/ajmc.2021.88808.","journal-title":"Am J Manag Care"},{"issue":"11","key":"1611_CR55","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1007\/s13300-020-00923-w","volume":"11","author":"M Willis","year":"2020","unstructured":"Willis M, Asseburg C, Slee A, Nilsson A, Neslusan C. Development and internal validation of a discrete event simulation model of diabetic kidney disease using CREDENCE trial data. Diabetes Ther. 2020;11(11):2657\u201376. https:\/\/doi.org\/10.1007\/s13300-020-00923-w.","journal-title":"Diabetes Ther"},{"key":"1611_CR56","unstructured":"American Society of Transplantation. Guidelines for post-kidney transplant management in the community setting. Available from: https:\/\/www.healthytransplant.com\/guidelines-post-kidney-transplant-management-community-setting-0. Accessed 13 Mar 2026."},{"issue":"15","key":"1611_CR57","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1001\/jama.2023.1792","volume":"329","author":"PJ Neumann","year":"2023","unstructured":"Neumann PJ, Kim DD. Cost-effectiveness thresholds used by study authors, 1990-2021. JAMA. 2023;329(15):1312\u20134. https:\/\/doi.org\/10.1001\/jama.2023.1792.","journal-title":"JAMA"},{"key":"1611_CR58","unstructured":"Kidney Research UK. Kidney disease: a UK public health emergency. The health economics of kidney disease to 2033. https:\/\/www.kidneyresearchuk.org\/wp-content\/uploads\/2023\/06\/Economics-of-Kidney-Disease-full-report_accessible.pdf. Accessed 13 Mar 2026."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01611-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01611-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01611-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:41:20Z","timestamp":1779201680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-026-01611-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,22]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1611"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01611-6","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,22]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Josep Darb\u00e0, Meritxell Ascanio, and Antonio Rodr\u00edguez have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The articles included in this systematic literature review were retrieved from the PubMed and Cochrane Library databases and supplemented with data from the NICE and NCBI websites. To harmonize the reported economic outcomes, all monetary values were adjusted to 2025 US dollars. Currency conversions were performed using exchange rates from\n                      \n                      and inflation adjustments were applied using the US Inflation Calculator.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"JD contributed to the investigation by interpreting the economic burden of CKD and played a major role in the intellectual content revision. MA and AR conducted the literature search, analyzed and interpreted the statistical data, and contributed to the writing of the manuscript. All authors read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}